{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-25-000006","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.902047+00:00","generated_at":"2026-05-25T13:52:53.160310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeuroPace reports Q4 revenue $21.5M (+19% YoY); guides FY2025 revenue $92-96M","bullets":["Q4 2024 revenue $21.5M (+19% YoY); full year revenue $79.9M (+22%).","Net loss improved: Q4 $5.3M (vs $6.2M); full year $27.1M (vs $33.0M).","FY2025 guidance: revenue $92-96M (15-20% growth), gross margin 73-75%, operating expenses $92-95M.","Completed $74.8M public offering; used $49.5M to repurchase 5.3M shares from KCK Ltd.; pro forma cash $68.6M.","NAUTILUS study completes March 2025; FDA submission H2 2025; NEST pediatric program for indication expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-25-000006","json":"https://secwatch.observer/filing/0001528287-25-000006.json","markdown":"https://secwatch.observer/filing/0001528287-25-000006.md","text":"https://secwatch.observer/filing/0001528287-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828725000006/0001528287-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828725000006/npce-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T13:52:53.160310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}